[1]
Thaci, D., Papp, K., Gordon, K., Morita, A., Gooderham, M., Foley, P., Alemano, E., Kisa, R., Elbez, Y., Ren, H. and Banerjee, S. 2019. An oral, selective tyrosine kinase 2 inhibitor, BMS-986165, improves quality of life in psoriasis: results from a Phase 2 study. SKIN The Journal of Cutaneous Medicine. 3, (Nov. 2019), S12. DOI:https://doi.org/10.25251/skin.3.supp.12.